Literature DB >> 27940386

Could PANSS be a useful tool in the determining of the stages of schizophrenia? A clinically operational approach.

Elena Dragioti1, Tobias Wiklund2, Melina Siamouli3, Katerina Moutou3, Konstantinos N Fountoulakis3.   

Abstract

Staging in schizophrenia might be an important approach for the better treatment and rehabilitation of patients. The purpose of this study was to empirically devise a staging approach in a sample of stabilized patients with schizophrenia. One hundred and seventy patients aged ≥18 years (mean = 40.7, SD = 11.6) diagnosed by DSM-5 criteria were evaluated with the Positive and Negative Syndrome Scale (PANSS). Principal components analysis (PCA) with varimax rotation was used. The model was examined in the total sample and separately across a hypothesized stage of illness based on three age groups and between the two sexes. The PCA revealed a six factor structure for the total sample: 1) Negative, 2) Positive, 3) Depression and anxiety, 4) Excitement and Hostility, 5) Neurocognition and 6) Disorganization. The separate PCAs by stage of illness and sex revealed different patterns and quality of symptomatology. The Negative and Positive factors were stable across all examined groups. The models corresponding to different stages differed mainly in terms of neurocognition and disorganization and their interplay. Catatonic features appear more prominent in males while in females neurocognition takes two forms; one with disorganization and one with stereotype thinking with delusions. This study suggests that the three arbitrary defined stages of illness (on the basis of age) seem to reflect a progress from a preserved insight and more coherent mental functioning to disorganization and eventually neurocognitive impairment. Sexes differ in terms of the relationship of psychotic features with neurocognition. These results might have significant research and clinical implications.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Evaluation; PANSS; Pyramidal model; Schizophrenia; Staging; Symptoms

Mesh:

Year:  2016        PMID: 27940386     DOI: 10.1016/j.jpsychires.2016.11.013

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  6 in total

1.  Main Symptomatic Treatment Targets in Suspected and Early Psychosis: New Insights From Network Analysis.

Authors:  Natalia Jimeno; Javier Gomez-Pilar; Jesus Poza; Roberto Hornero; Kai Vogeley; Eva Meisenzahl; Theresa Haidl; Marlene Rosen; Joachim Klosterkötter; Frauke Schultze-Lutter
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

2.  Brief Clinical Assessment Scale for Schizophrenia (BCASS): Development, Validity, and Reliability Study.

Authors:  Mustafa Yildiz; Aysel Incedere; Mehmet Buğrahan Gürcan; Emre Osman
Journal:  Noro Psikiyatr Ars       Date:  2021-08-04       Impact factor: 1.339

3.  The component structure of the scales for the assessment of positive and negative symptoms in first-episode psychosis and its dependence on variations in analytic methods.

Authors:  Marc S Tibber; James B Kirkbride; Eileen M Joyce; Stanley Mutsatsa; Isobel Harrison; Thomas R E Barnes; Vyv Huddy
Journal:  Psychiatry Res       Date:  2018-10-30       Impact factor: 3.222

4.  Is it possible to stage schizophrenia? A systematic review.

Authors:  Clara Martínez-Cao; Lorena de la Fuente-Tomás; Ainoa García-Fernández; Leticia González-Blanco; Pilar A Sáiz; María Paz Garcia-Portilla; Julio Bobes
Journal:  Transl Psychiatry       Date:  2022-05-11       Impact factor: 7.989

5.  Exploring the link between cognitive deficit, self-esteem, alexithymia, and depressive symptom of schizophrenia.

Authors:  Chen He; Xueying Zhang; Qingrong Xia; Hua Gao; Junwei Yan; Xuequan Chen; Hui Yuan; Yang Zhang; Wen Xie; Cuizhen Zhu
Journal:  Brain Behav       Date:  2022-06-08       Impact factor: 3.405

6.  Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study.

Authors:  Konstantinos N Fountoulakis; Elena Dragioti; Antonis T Theofilidis; Tobias Wikilund; Xenofon Atmatzidis; Ioannis Nimatoudis; Erik Thys; Martien Wampers; Luchezar Hranov; Trayana Hristova; Daniil Aptalidis; Roumen Milev; Felicia Iftene; Filip Spaniel; Pavel Knytl; Petra Furstova; Tiina From; Henry Karlsson; Maija Walta; Raimo K R Salokangas; Jean-Michel Azorin; Justine Bouniard; Julie Montant; Georg Juckel; Ida S Haussleiter; Athanasios Douzenis; Ioannis Michopoulos; Panagiotis Ferentinos; Nikolaos Smyrnis; Leonidas Mantonakis; Zsófia Nemes; Xenia Gonda; Dora Vajda; Anita Juhasz; Amresh Shrivastava; John Waddington; Maurizio Pompili; Anna Comparelli; Valentina Corigliano; Elmars Rancans; Alvydas Navickas; Jan Hilbig; Laurynas Bukelskis; Lidija Injac Stevovic; Sanja Vodopic; Oluyomi Esan; Oluremi Oladele; Christopher Osunbote; Janusz Κ Rybakowski; Pawel Wojciak; Klaudia Domowicz; Maria Luisa Figueira; Ludgero Linhares; Joana Crawford; Anca-Livia Panfil; Daria Smirnova; Olga Izmailova; Dusica Lecic-Tosevski; Henk Temmingh; Fleur Howells; Julio Bobes; Maria Paz Garcia-Portilla; Leticia García-Alvarez; Gamze Erzin; Hasan Karadağ; Avinash De Sousa; Anuja Bendre; Cyril Hoschl; Cristina Bredicean; Ion Papava; Olivera Vukovic; Bojana Pejuskovic; Vincent Russell; Loukas Athanasiadis; Anastasia Konsta; Dan Stein; Michael Berk; Olivia Dean; Rajiv Tandon; Siegfried Kasper; Marc De Hert
Journal:  Int J Neuropsychopharmacol       Date:  2019-11-01       Impact factor: 5.176

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.